Cervical Health, Hormones, and BHRT: What Every Woman Should Know About Pap Smears
Pap smears are one of the most effective cancer screening tools in medicine. Since the widespread adoption of cervical cytology screening in the mid-20th century, cervical cancer rates in the United States have fallen by more than 70 percent. And yet many women — particularly those navigating perimenopause, menopause, and hormone therapy — have questions about how hormonal changes affect their cervical health, how BHRT interacts with Pap smear results, and when they can safely stop screening.
What a Pap Smear Actually Tests
A Pap smear (Papanicolaou test) collects cells from the cervix and examines them under a microscope for abnormal changes that may indicate precancerous conditions or cancer. Most cervical cancers are caused by persistent infection with high-risk strains of human papillomavirus (HPV), and the HPV co-test — often performed alongside the Pap smear — directly tests for the presence of these high-risk strains.
Current guidelines from the U.S. Preventive Services Task Force recommend cervical cancer screening every three years with Pap smear alone for women aged 21–65, or every five years with combined Pap and HPV testing for women aged 30–65. Women who have had a hysterectomy with removal of the cervix and no history of high-grade precancerous lesions or cervical cancer generally do not need continued Pap smears.
How Hormonal Changes Affect Cervical Tissue
Estrogen plays an important role in the health and maintenance of cervical and vaginal epithelial tissue. The cervix is covered by two types of cells — squamous cells on the outer portion (ectocervix) and glandular cells in the cervical canal (endocervix) — and both are influenced by estrogen. During the reproductive years, estrogen keeps these tissues well-hydrated, elastic, and resistant to microtrauma.
After menopause, when estrogen levels decline, cervical and vaginal tissues undergo atrophic changes. The epithelium becomes thinner, dryer, and more fragile. This atrophy is not cancerous, but it can cause cellular changes on a Pap smear that may look abnormal to a pathologist unfamiliar with the patient's menopausal status — potentially leading to unnecessary follow-up procedures.
This is called atrophic vaginitis or atrophic cervicitis, and it is a benign consequence of estrogen deficiency. On a Pap smear, atrophic changes can produce findings labeled as "atypical squamous cells of undetermined significance" (ASCUS) when the underlying cause is simply estrogen deprivation rather than a precancerous process. Informing your pathologist and gynecologist that you are postmenopausal and not on estrogen therapy ensures that results are interpreted in the correct hormonal context.
BHRT and Pap Smear Interpretation
Women on BHRT — particularly those using systemic or local estrogen — typically maintain better cervical and vaginal tissue quality than women without estrogen replacement. Well-estrogenized cervical epithelium is healthier, more resilient, and produces more representative cell samples on Pap smear.
For postmenopausal women who have received ASCUS Pap results and are not on estrogen therapy, a common approach is to prescribe a short course of vaginal estrogen and repeat the Pap smear in a few months. Frequently, the repeat smear is normal, confirming that atrophy — not dysplasia — was responsible for the initial abnormal result. This is another reason why maintaining appropriate estrogen levels matters for cervical health, not just for systemic wellbeing.
BHRT does not cause cervical cancer and does not cause abnormal Pap results in women with healthy cervical tissue. HPV infection remains the primary cause of abnormal cytology and cervical cancer regardless of hormonal status.
Local Vaginal Estrogen vs. Systemic BHRT
For women whose primary concern is vaginal and cervical atrophy, low-dose vaginal estrogen (available as creams, rings, or suppositories) delivers estrogen locally to the vaginal and cervical tissues with minimal systemic absorption. This option is appropriate for women who prefer to avoid or cannot use systemic hormone therapy, and it is highly effective for reversing atrophic changes and reducing genitourinary symptoms of menopause.
Systemic BHRT — estradiol delivered via patch, gel, pellet, or oral route — also supports vaginal and cervical tissue while providing the broader systemic benefits of estrogen restoration. The appropriate route depends on individual symptoms, risk factors, and goals.
Do Not Skip Your Screening
Despite the reassuring data on hormone therapy and cervical health, Pap smear and HPV co-testing at recommended intervals remain essential. BHRT does not substitute for cervical cancer screening. Regular gynecologic care, including pelvic examination and cervical cytology, is the foundation of cervical health monitoring regardless of hormonal status.
Women who are managing their hormonal health proactively are often the same women who are most attentive to preventive screening — and that combination is powerful for long-term health outcomes.
Kenton Bruice, M.D. integrates hormonal health management with a broader commitment to preventive medicine. If you have questions about how BHRT interacts with your gynecologic health or cervical screening results, schedule a consultation at his Denver, Aspen, or St. Louis practice for individualized guidance.